Case 30-2008
Authors:
- Jennifer R. BellonJBJennifer R. Bellon
- Michele A. GaddMGMichele A. Gadd
- Helen Anne D'AlessandroHDHelen Anne D'Alessandro
- Kristina BraatenKBKristina Braaten
- 25 September 2008
- journal article
- case report
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 359 (13) , 1382-1391
Abstract
A 47-year-old premenopausal woman came to this hospital for treatment of breast cancer. A mass that measured 5 cm in diameter was present in the left breast; needle biopsies showed infiltrating ductal carcinoma that was grade 2 of 3, hormone receptor–positive, HER2/neu-negative. An evaluation of the staging disclosed a solitary lesion in the T6 vertebral body, which was asymptomatic. A management decision was made.Keywords
This publication has 39 references indexed in Scilit:
- Local Therapy and Survival in Breast CancerNew England Journal of Medicine, 2007
- Is Liver Resection Justified for Patients With Hepatic Metastases From Breast Cancer?Annals of Surgery, 2006
- The utility of estrogen receptor, progesterone receptor, and Her-2/neu status to predict survival in patients undergoing hepatic resection for breast cancer metastasesThe American Journal of Surgery, 2006
- Combined‐modality treatment for isolated recurrences of breast carcinomaCancer, 2005
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trialThe Lancet, 2004
- New prognostic factors for breast cancer recurrenceSeminars in Oncology, 2001
- Hepatic resection in metastatic breast cancer: results and prognostic factorsEuropean Journal of Surgical Oncology, 2000
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991
- The Depot GnRH Analogue Goserelin in the Treatment of Premenopausal Patients with Metastatic Breast Cancer -A 5-Year Experience and further Endocrine TherapiesOncology Research and Treatment, 1991
- Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancerBreast Cancer Research and Treatment, 1984